Jump To Topic
The Biomet M2a-Magnum is a metal-on-metal hip implant that is marketed as more durable and easily customized to better fit different patients. For all the advantages that the implant is supposed to possess–which also include better range of motion and reduced risk of dislocation–it also carries the same risk of side effects as other metal-on-metal implants.
While Biomet has not recalled the implant, it does recommend that patients who receive an M2a-Magnum regularly monitor the status of their device with their doctor. The FDA has issued numerous notices expressing concern over MoM implants and calling for further postmarket studies and a more comprehensive national registry system.
Of the more than 12,000 adverse incident reports filed with the FDA in 2011 that pertained to hip implants, nearly three quarters involved metal-on-metal devices. (The majority of those complaints were about implants manufactured by DePuy.) In 2013, the UK banned MoM hip implants outright after its own national patient data demonstrated unacceptably high failure rates.
Biomet Lawsuit Allegations
Biomet lawsuits allege that the M2a-Magnum is a defective product. Like other MoM implants, its design releases metal ions into the body that can cause severe side effects, such as metallosis and device failure. The large surface area of its head may exacerbate these side effects and may cause a localized reaction even without releasing debris. However, there is evidence that the Biomet implant is less prone to complications than some other MoM implants.
Lawsuits were combined into multidistrict litigation in Indiana, Biomet’s home state.